drugset / Trial / NCT00798629
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
Phase 1
Completed
13 enrolled
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic melanoma.
Timeline
- Start
- 2008-11
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OVEMOTIDE | Cell therapy | 2e+06 cells | Intramuscular |
| Subject | OVEMOTIDE | Cell therapy | 1e+07 cells | Intramuscular |
| Subject | OVEMOTIDE | Cell therapy | 2e+07 cells | Intramuscular |